Himalayas-1 randomizes 1:1 to rinzimetostat 400 mg daily plus darolutamide vs physician’s choice ARPI or docetaxel in mCRPC progressing after abiraterone. Radiographic PFS is the primary end point, ...

The following FAQs highlight key recommendations and practical takeaways from the 2026 AUA/SUO Advanced Prostate Cancer Guideline. Two overarching themes define the 2026 amendment: the consolidation ...

FDA Breakthrough Device Designation was granted to an AI-powered H&E-based prognostic assay for bladder cancer, described as the first such designation in this disease setting. Proprietary foundation ...

Random assignment of 1018 patients showed durable DFS improvement with durvalumab+BCG induction/maintenance vs BCG (12-to-48 month DFS: 92%–80% vs 87%–75%), while ...

The management of testicular cancer continues to evolve, with advances in diagnostics, risk stratification, and multimodal treatment shaping contemporary clinical practice. At the 41st Annual Congress ...

FDA is encouraging NDA holders for gels, patches, and injectables to discuss sNDAs for treating low libido in idiopathic hypogonadism, a group currently excluded from labeled indications. April 30, ...

The first-ever guideline on genitourinary syndrome of menopause (GSM) was released, providing evidence-based guidance for managing this condition in urologic care. The FDA removed the black box ...

Experts recommend removing unsupported prostate cancer warnings from TRT labels and aligning indications with professional guidelines. Testosterone's Schedule III classification creates barriers to ...

IsoPSA, a blood-based test, aids in diagnosing high-grade prostate cancer by analyzing PSA protein structural variants. FDA approval was based on a large-scale, prospective study and other validation ...

ORIC-944 demonstrated significant anti-tumor activity and tolerability in combination with ARPIs in mCRPC patients. The phase 1b trial showed notable PSA and ctDNA reductions across all ORIC-944 dose ...

The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...

Nocturnal enuresis affects millions, including adolescents and adults, and is not the child's fault but a sleep-related condition outside conscious control. Current treatments, including behavioral ...